Assembly Biosciences Shares Insights on Upcoming Conferences

Author: Evelyn Baker Updated: 10-14-2025 07:21 AM

Assembly Biosciences Set to Engage at Investor Conferences

Assembly Biosciences, Inc. (NASDAQ: ASMB), renowned for its innovative biotechnology solutions, has exciting plans to join discussions at two significant investor conferences soon. This engagement demonstrates their dedication to advancing therapeutics targeting serious viral diseases.

Participation in Major Conferences

Assembly Biosciences will participate in notable fireside chats that provide insights into their ongoing projects and future directions. These conferences are great platforms for the company to engage with investors and share their achievements in therapeutic developments.

H.C. Wainwright Liver Disease Virtual Conference

Dr. Anuj Gaggar, who serves as the Chief Medical Officer, will present a pre-recorded fireside chat during the H.C. Wainwright Liver Disease Virtual Conference. This presentation will be accessible on-demand starting in the early hours of October 21, 2025. It promises to offer valuable insights into the company's advancements in addressing liver diseases through their innovative therapies.

Guggenheim 2nd Annual Healthcare Innovation Conference

At the Guggenheim 2nd Annual Healthcare Innovation Conference, scheduled for November 12, 2025, at 11 a.m. Eastern Time, Jason Okazaki, the CEO and President, along with Dr. Gaggar, will engage in a fireside chat. Their discussion will likely highlight the promising potential of their drug candidates and the ongoing strategies that aim to enhance patient outcomes.

The Mission of Assembly Biosciences

Assembly Biosciences is on a mission to create groundbreaking small-molecule therapeutics designed to significantly improve the treatment of serious viral infections like herpesvirus, hepatitis B (HBV), and hepatitis delta virus (HDV). With a team of industry veterans in virologic drug development, the company is committed to transforming the lives of patients affected by these conditions.

Insights into Innovative Therapeutics

Through committed research and development, Assembly is at the forefront of creating therapies that address the long-term challenges faced by patients with chronic viral infections. The upcoming conferences will spotlight how these innovations can potentially reshape the therapeutic landscape.

Contacting Assembly Biosciences

Investor Relations

For additional details or inquiries regarding their investor activities, you can reach out to Shannon Ryan, Senior Vice President of Investor Relations, Corporate Affairs, and Alliance Management at (415) 738-2992 or via email at investor_relations@assemblybio.com.

Media Contacts

For media-related questions, the team at Sam Brown LLC can be contacted. Alyssa Kuciunas is reachable at (331) 481-3751, or by email at ASMBMedia@sambrown.com.

Frequently Asked Questions

What major conferences will Assembly Biosciences attend?

They will participate in the H.C. Wainwright Liver Disease Virtual Conference and the Guggenheim 2nd Annual Healthcare Innovation Conference.

Who is the CEO of Assembly Biosciences?

Jason Okazaki serves as the CEO and President.

What is the focus of Assembly Biosciences?

The company develops innovative therapeutics targeting viral diseases, focusing particularly on herpesvirus and hepatitis infections.

How can I register for the webcasts?

Registrations can be made through the Events and Presentations section of Assembly Biosciences' website.

What are Assembly's future plans for therapeutics?

The company continues to focus on advancing therapeutic development for serious viral diseases, aiming to enhance patient outcomes significantly.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.